37 completed, 5 unknown, 5 withdrawn, 1 active not recruiting. 15 Phase 2, 12 Not applicable, 10 Phase 4, 8 Phase 3, 5 Phase 1.
Follow pramlintide: new trials by email Literature Review of pramlintide trials Research Report on pramlintide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans Amylin (Pramlintide), Pancreatic Polypeptide (PP), Placebo (NaCl 0.9 % solution) - Obesity & Overweight | Not applicable | Recruiting | University Hospital, Gentofte, Copenhagen | 18 | 2026-04-01 | 2026-04-01 |
| Tailoring Obesity Treatment Trial Pramlintide Acetate 1 MG/ML, Semaglutide Pen Injector, Sodium Chloride 0.9% Inj - Obesity, Appetite Regulation | Phase 2 / Phase 3 | Withdrawn | Esbjerg Hospital - University Hospital of Southern Denmark | 2025-04-01 | 2026-04-17 | |
| The Role of Amylin in Bone Metabolism Pramlintide, Placebo (saline) infusion - Bone Diseases, Metabolic, Type 1 Diabetes | Not applicable | Unknown | Filip Krag Knop | 20 | 2024-02-12 | 2024-02-21 |
| A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes Pramlintide, Lyumjev, Automated Insulin Delivery (AID) system - type1diabetes, Diabetes Mellitus, Type 1 | Phase 2 / Phase 3 | Unknown | McGill University Health Centre/Research Institute of the McGill University Health Centre | 30 | 2023-11-30 | 2024-04-18 |
| A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes Fiasp, Artificial Pancreas, Pramlintide - Type 1 Diabetes | Not applicable | Completed | McGill University Health Centre/Research Institute of the McGill University Health Centre | 12 | 2022-02-21 | 2023-10-25 |
| Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes Rapid-Acting Insulin, Placebo, Pramlintide Acetate - Diabetes Mellitus, Type 1, Type 1 Diabetes | Not applicable | Unknown | McGill University | 26 | 2021-11-12 | 2023-03-15 |
| Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas Fiasp, Pramlintide Acetate, Placebo - Type 1 Diabetes, Type 1 Diabetes Mellitus | Not applicable | Completed | McGill University | 36 | 2020-02-14 | 2022-10-10 |
| Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease Pramlintide challenge test - Alzheimer Disease, Mild Cognitive Impairment | Early Phase 1 | Active not recruiting | Boston University | 57 | 2020-02-04 | 2026-05-28 |
| Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study Pramlintide - Cutaneous Squamous Cell Carcinoma | Early Phase 1 | Withdrawn | H. Lee Moffitt Cancer Center and Research Institute | 2020-01-30 | 2023-06-28 | |
| Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D PRAM9, Regular Insulin + Pramlintide, Regular Insulin - Diabetes Mellitus, Type 1, Insulin-dependent Diabetes Mellitus | Phase 2 | Completed | Xeris Pharmaceuticals | 18 | 2019-08-22 | 2024-03-27 |
| A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus ADO09 formulation, Placebo, Symlin® - Type 1 Diabetes Mellitus | Phase 1 | Completed | Adocia | 24 | 2019-01-04 | 2019-04-16 |
| Amylin and CGRP Head to Head Provocation in Migraine Without Aura Patients Amylin (Pramlintide), CGRP - Migraine Without Aura | Not applicable | Completed | Danish Headache Center | 36 | 2018-07-01 | 2020-06-25 |
| A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus BC Pram Ins, Symlin® and Humulin®, Humalog® - Type 1 Diabetes Mellitus | Phase 1 | Completed | Adocia | 24 | 2018-04-25 | 2019-02-21 |
| Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus Pramlintide acetate, Placebo, Lispro insulin U-100 - Type 1 Diabetes Mellitus | Phase 1 | Completed | AstraZeneca | 34 | 2015-08-17 | 2018-11-02 |
| Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM Pramlintide acetate, Placebo - Type 1 Diabetes | Phase 1 | Completed | AstraZeneca | 32 | 2012-11-01 | 2014-10-20 |
| Pramlintide Combined With Model Predictive Control Algorithm Closed loop with pramlintide, Closed loop without pramlintide, Open loop with pramlintide - Type 1 Diabetes Mellitus | Not applicable | Terminated | University of Virginia | 2 | 2011-02-01 | 2014-05-01 |
| Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus Pramlintide - Type 2 Diabetes Mellitus | Phase 3 | Unknown | Cheryl Rosenfeld, DO | 40 | 2010-05-01 | 2011-10-14 |
| Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery Pramlintide - Hypoglycemia, Evidence of Previous Gastric Surgery | Phase 4 | Completed | Joslin Diabetes Center | 22 | 2010-02-02 | 2023-06-29 |
| Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus Pramlintide - Diabetes Mellitus | Phase 1 / Phase 2 | Withdrawn | University of Colorado, Denver | 2009-08-01 | 2018-07-26 | |
| Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia Pramlintide, Exenatide, Insulin - Type 1 Diabetes | Phase 4 | Completed | Albert Einstein College of Medicine | 37 | 2009-08-01 | 2018-04-12 |
Showing 20 of 50. Sign in to see all of them.
Diabetes Mellitus, Type 1 (28) · Obesity (11) · Diabetes Mellitus, Type 2 (10) · Diabetes Mellitus (9) · Hyperglycemia (5) · Insulin Resistance (5) · Overweight (5) · Hypoglycemia (4) · Weight Gain (2) · Weight Loss (2) · Alzheimer Disease (1) · Bone Diseases, Metabolic (1) · Cognitive Dysfunction (1) · Metabolic Syndrome (1) · Migraine without Aura (1)
AstraZeneca (19) · Baylor College of Medicine (4) · Adocia (2) · McGill University (2) · McGill University Health Centre/Research Institute of the McGill University Health Centre (2) · University of Colorado, Denver (2) · University of Texas Southwestern Medical Center (2) · Albert Einstein College of Medicine (1) · Boston University (1) · Cheryl Rosenfeld, DO (1) · Danish Headache Center (1) · Diabetes Care Center (1) · Esbjerg Hospital - University Hospital of Southern Denmark (1) · Filip Krag Knop (1) · H. Lee Moffitt Cancer Center and Research Institute (1)
United States (36) · Canada (4) · Denmark (4) · Germany (2) · Australia (1)
Lisa Porter, MD (10) · Rubina Heptulla, MD (3) · Grit Andersen, MD (2) · Michael Tsoukas, M.D. (2) · Rubina A Heptulla, MD (2) · Ahmad Haidar, Ph.D. (1) · Alan Schorr, DO (1) · Allen B King, MD (1) · Andrea Valasquez (1) · Anthony McCall, M.D., Ph.D. (1) · Boris Draznin, M.D., Ph.D. (1) · Carol A Tamminga, MD (1) · Cheryl Rosenfeld, DO (1) · Claus Bogh Juhl, MD, phd, professor (1) · David M Huffman, MD (1)
PMID 26589105, PMID 15793249, PMID 18753666, PMID 23748514, PMID 17109671, PMID 17425446, PMID 17698615, PMID 18031595, PMID 18715216, PMID 19049375, PMID 19190104, PMID 19546056, PMID 19858155, PMID 20199136, PMID 20518811, PMID 26040429, PMID 30213882, PMID 38906614
K23DK075931 (1), R01AG059424 (1), R01DK077166 (1)